Home › Forums › Other Specialities › Therapeutics › CHOLESTEROL LOWERING -NEW INJECTABLE DRUG.
- This topic has 0 replies, 1 voice, and was last updated 9 years, 8 months ago by
Anonymous.
-
AuthorPosts
-
-
June 11, 2015 at 2:05 am #2740
Anonymous
InactiveNew lipid-lowering antibody evolocumab provides additional benefit to statins-Licensed in UK.
Evolocumab (Repatha) is the first in a new class of injectable cholesterol-lowering treatments known as PCSK9 inhibitors.In studies, evolocumab reduced LDL-C by up to 75% in patients already taking statins.
The antibody binds to the PCSK9 enzyme (proprotein convertase subtilisin/kexin type 9), preventing PCSK9-mediated degradation of LDL receptors on the liver cell surface and thus increasing metabolism of LDL-C.
“It is over a decade since the last new drug class for cholesterol-lowering therapy was introduced in the UK,” said Dr Dermot Neely, lead consultant for the lipid and metabolic outpatient clinic at the Royal Victoria Infirmary in Newcastle.
“We now have a new treatment option which may be considered in patients who are resistant to statins or unable to take them. In particular, our patients with severe forms of FH frequently have persistently raised cholesterol levels and remain at serious risk of having a heart attack or stroke, despite a healthy diet, healthy lifestyle and currently available lipid-lowering treatments in maximum combinations.”
Self-administration
Supplied in a prefilled syringe or SureClick pen, Repatha is given by subcutaneous injection monthly or fortnightly and is intended for patients to self-administer following appropriate training.Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial or non-familial) or mixed dyslipidaemia, as an adjunct to diet:
in combination with a statin with or without other lipid-lowering therapies in patients unable to reach LDL-C goals with a statin alone, or
alone or in combination with other lipid-lowering therapies in patients who cannot take a statin.
Repatha is also indicated in combination with other lipid-lowering therapies in adults and adolescents from 12 years with homozygous familial hypercholesterolaemia.TAUSSIG is an ongoing 5-year study assessing the long-term effects of evolocumab in patients with severe familial (including homozygous) hypercholesterolaemia. Interim results showed a sustained 48% reduction in LDL-C at 36 weeks.
Nasopharyngitis
The most commonly reported adverse reactions of evolocumab were nasopharyngitis (4.8%), upper respiratory tract infection (3.2%), back pain (3.1%), arthralgia (2.2%), influenza (2.3%) and nausea (2.1%).
Comment-G Mohan – new class of drugs, with good potential, 5 yr studies in various clinical scenes showing good promise , with no worrying side effects so far noticed. Would need longer follow up studies , particularly in different Ethnic groups.
-
-
AuthorPosts
- You must be logged in to reply to this topic.